Stock Events

Stock Events

Biofrontera 

€2.52
58
+€0.25+11.01% 14:33 Today

Statistics

Day High
2.52
Day Low
2.52
52W High
2.52
52W Low
2.48
Volume
0.49
Avg. Volume
-
Mkt Cap
32.26M
P/E Ratio
0.04
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.98
-0.66
-0.34
-0.03
Expected EPS
-0.105
Actual EPS
N/A

Financials

-25.63%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
36.13MRevenue
-9.26MNet Income

Analyst Ratings

2.28Average Price Target
The highest estimate is 2.28.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0DOL.LSE. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
AMD
8
AMD
Tesla
7
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap293.94B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Show more...
CEO
Dr. Hermann Lubbert Ph.D.
Employees
95
Country
Germany
ISIN
DE000A4BGGM7

Listings

XNAS
US
BFRI
MU
DE
B8FK.MU
MU
DE
AI1.MU
STU
DE
AI10.STU

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼
The current price of 0DOL.LSE is €2.52 EUR — it has increased by +11.01% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Biofrontera stocks are traded under the ticker 0DOL.LSE.
What is Biofrontera market cap?▼
Today Biofrontera has the market capitalization of 32.26M
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on August 07, 2026.
What were Biofrontera earnings last quarter?▼
0DOL.LSE earnings for the last quarter are -0.35 EUR per share, whereas the estimation was -0.1 EUR resulting in a -256.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 36.13M EUR.
What is Biofrontera net income for the last year?▼
0DOL.LSE net income for the last year is -9.26M EUR.
How many employees does Biofrontera have?▼
As of July 22, 2026, the company has 95 employees.
In which sector is Biofrontera located?▼
Biofrontera operates in the Energy sector.
When did Biofrontera complete a stock split?▼
The last stock split for Biofrontera was on May 14, 2024 with a ratio of 1:21.
Where is Biofrontera headquartered?▼
Biofrontera is headquartered in Leverkusen, Germany.